IL-18 revives dysfunctional CAR-T cells
Trends in Cancer · 2025
DOI: 10.1016/j.trecan.2025.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Cancer, 2025. Verfasst von Yan-Ruide Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengi…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Interleukin-18, Lymphoma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California Los Angeles.
Abstract (Originalsprache)
IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095,…
Förderung
- University of California Los Angeles
Zitieren
APA
Li, Y. R., Zhu, Y., & Yang, L. (2025). IL-18 revives dysfunctional CAR-T cells. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.06.008
Vancouver
Li YR, Zhu Y, Yang L. IL-18 revives dysfunctional CAR-T cells. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.06.008
BibTeX
@article{Li2025,
author = {Li, Yan-Ruide and Zhu, Yichen and Yang, Lili},
title = {IL-18 revives dysfunctional CAR-T cells},
journal = {Trends in Cancer},
year = {2025},
doi = {10.1016/j.trecan.2025.06.008}
}
EUVIMED